~ ~ The Second Study Fully Enrolled for Breakthrough Therapy-Designated, First-in-Class Opioid Desig

~ ~ The Second Study Fully Enrolled for Breakthrough Therapy-Designated, First-in-Class Opioid Desig

~Major symposium to highlight breakthrough innovations in severe pain and Complex Regional Pain Synd

Ensysce Biosciences, Inc. (ENSC) Discusses Acquisition of Cy Biopharma and Private Placement Financi

Gainers iTonic Holdings (NASDAQ:ITOC) stock moved upwards by 32.0% to $0.41 during Friday's aft

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.20) per share which beat the anal

Acquisition of Cy Biopharma Completed, Adding CY200 for Complex Regional Pain Syndrome Up to $77 mil

Gainers Liminatus Pharma (NASDAQ:LIMN) stock increased by 48.4% to $0.16 during Thursday's regu

Ensysce Biosciences (NASDAQ: ENSC - Get Free Report) and CannAmerica Brands (OTCMKTS:CNNXF - Get Fre

Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday'

US stocks trade mixed, Nasdaq falls 50 points. Energy shares up 1.3%, tech stocks down 0.5%. US Food

Acquisition includes clinical-stage neuroplastogenic therapy with U.S. FDA Orphan Drug Designation f

Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 86.9% to $1.25 during Thursday's

Acquisition includes clinical-stage neuroplastogenic therapy with U.S. FDA Orphan Drug Designation f

Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 415.3% to $18.81 during Tuesday's regular se

Gainers Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 55.4% to $0.44 during Tuesday'

Palantir Technologies Inc (PLTR) shares jumped 16.1% in pre-market trading on upbeat Q2 results, wit

Gainers Ensysce Biosciences (NASDAQ:ENSC) stock rose 118.1% to $0.61 during Monday's after-mark

https://x.com/PatentGrants/status/2084367854472954161https://patentcenter.uspto.gov/applications/174

Gainers NextCure (NASDAQ:NXTC) shares rose 305.5% to $8.84 during Tuesday's pre-market session.

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-sta

Funds Advance FDA-Designated Breakthrough Therapy First-in-Class Opioid with Oral Overdose-Protectio

Gainers Seer (NASDAQ:SEER) stock moved upwards by 33.3% to $2.16 during Thursday's after-market

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-sta

~ ~ Advances First-in-Class, Breakthrough Therapy-Designated Opioid Engineered to Protect Against Or

~ IRB Approval Secured for PF614-MPAR-102 Part 3 ~ ~ Clinical Peer-Reviewed Data Published for First

~ Patent Extends Jurisdiction and Protection Through 2042 ~ SAN DIEGO, CA / ACCESS Newswire / May 12

~ Chemical Control, Clinical Confidence: Rethinking Opioids ~ SAN DIEGO, CA / ACCESS Newswire / May

~ Advances First-in-Class Opioid with Oral Overdose-Protection ~ SAN DIEGO, CA / ACCESS Newswire / A

~Continued funding underscores investor confidence and supports advancement of abuse- and overdose-r

~ Fourth Quarter Highlighted by Clinical and Regulatory Milestones Positioning PF614 for Late-Stage

Ensysce Biosciences, Inc. (NASDAQ: ENSC - Get Free Report) was the target of a significant drop in s

~ Underscores Strategic Execution Plans, Regulatory Risk Mitigation Efforts, Pipeline Prioritization

~ Phase 1 Data Published in Journal of Opioid Management Validates First-in-Class Overdose-Limiting

Ensysce Biosciences (NASDAQ: ENSC) shares are up on Friday as the company has initiated a review of

US stocks traded lower, Dow down 600 points. Nasdaq and S&P also fell. Consumer staples up, tech

Review Includes Strategic Partnerships, Licensing and Other Corporate Transactions Focused on Advanc

~ Company leadership to highlight TAAP and MPAR programs, discuss innovation in pain therapeutics an